Pérez D, Tincani A, Serrano M, Shoenfeld Y, Serrano A
1 Department of Immunology, 16473 Hospital Universitario 12 de Octubre , Madrid, Spain.
2 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Aviv, Israel.
Lupus. 2018 Feb;27(2):177-178. doi: 10.1177/0961203317738227. Epub 2017 Oct 25.
IgA anti-beta2-glycoprotein I (IgA-aB2GPI) antibodies are currently not included as a laboratory criterion of antiphospholipid syndrome (APS). In the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, (USA) in 2010, these antibodies were accepted as an APS laboratory criterion in patients who had clinical manifestations of APS but were negative for "consensus" antiphospholipid antibodies (aPL) (IgG and IgM isotypes). Consequently, individuals with thrombotic events who are negative for consensus aPL may be undiagnosed for APS. The most recent publications have confirmed that IgA-aB2GPI antibodies are a risk factor for thrombotic events. In this viewpoint, we propose that IgA-aB2GPI antibodies should be included as an APS consensus criterion and that we have to help Cinderella become a princess.
IgA抗β2糖蛋白I（IgA-aB2GPI）抗体目前未被纳入抗磷脂综合征（APS）的实验室诊断标准。在2010年于美国得克萨斯州加尔维斯顿举行的第13届国际抗磷脂抗体大会上，这些抗体被接受为APS的实验室诊断标准，适用于那些有APS临床表现但“公认”抗磷脂抗体（aPL）（IgG和IgM亚型）检测呈阴性的患者。因此，共识aPL检测呈阴性的血栓形成事件患者可能未被诊断为APS。最新的出版物证实，IgA-aB2GPI抗体是血栓形成事件的一个危险因素。基于此观点，我们建议应将IgA-aB2GPI抗体纳入APS的共识诊断标准，并且我们必须帮助灰姑娘成为公主。
